ClinicalTrials.gg
RecruitingNCT07372027Updated Jan 28, 2026

Single-Needle Distal Return for Long-Term Arteriovenous Fistula Care

An interventional study of Single-Needle Distal Return (SNDR) Cannulation and Standard Two-Needle AVF Cannulation in Hemodialysis Access, Arteriovenous Fistula and Arteriovenous Fistula Cannulation, sponsored by Suzhou Municipal Hospital of Anhui Province. Recruiting at 1 site in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Suzhou Municipal Hospital of Anhui Province · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Arteriovenous Fistula with a site in China — 6 open to participants now, 7 under way, none of them phase 3. Arteriovenous Fistula · China.

Planned enrollment
11th of 14
100 · median 184
Started
2026
with 1 other
No phase
13 of 20
4 open now
Registered
19th of 20
by date

Among the 20 studies in Arteriovenous Fistula with a site in China, this one is the 11th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2026, is one of 13 with no phase, and was the 19th registered.

Arteriovenous Fistula

248 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.

Browse Arteriovenous Fistula studies →

Open to participants now

6 of the 20 studies in Arteriovenous Fistula with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Arteriovenous Fistula studies recruiting now, 13 (48%) set no upper age limit and 4 (15%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Arteriovenous Fistula with a site in China, or all of them as a file.
02

Study summary

Background:

For millions of people worldwide with kidney failure, a well-functioning vascular access, like an arteriovenous fistula (AVF), is essential for life-sustaining hemodialysis. However, the standard method requires puncturing the same AVF with two needles three times a week, which over time can damage the vessel, leading to scarring, narrowing, and frequent failures. These complications often require repeated surgical or minimally invasive procedures (reinterventions), causing significant pain, high medical costs, and exhaustion of the patient's limited blood vessels.

New Approach:

This study will evaluate a modified puncture technique called the Single-Needle Distal Return (SNDR) strategy for long-term AVF care. Instead of using two needles in the AVF, only one needle is placed in the AVF to draw blood. The cleaned blood is then returned to the body through a second needle placed in a superficial vein in the foot or lower leg. This approach aims to reduce trauma to the critical AVF.

Study Plan:

This is a clinical study conducted at the Blood Purification Center of Anhui Medical University Affiliated Suzhou Hospital. We plan to enroll approximately 50 adult hemodialysis patients who use an AVF and are willing to try the SNDR technique. For comparison, we will also observe data from a similar number of patients receiving standard two-needle AVF care during the same period.

The study will last about three years. We will closely monitor patients using the SNDR technique to assess:

Effectiveness: Whether dialysis remains adequate (measured by Kt/V).

Safety: Rates of complications (like bruising or infection), dialysis machine alarms, and venous pressure during treatment.

Practical Benefits: Whether it reduces the need for repair procedures (reinterventions) and hospitalizations related to the AVF.

Economic Impact: Changes in healthcare costs.

Patient Experience: Patient tolerance and comfort with the technique. We will also analyze the characteristics of patients who successfully use this technique long-term to help identify who might benefit most from it in the future.

Potential Significance:

If proven successful and safe for long-term use, the SNDR strategy could help protect a patient's precious AVF, potentially reducing painful procedures, lowering costs, slowing down the exhaustion of blood vessels, and improving the quality of life for people on long-term dialysis. The findings may also guide better planning for vascular access care.

03

Conditions studied

  • Hemodialysis Access
  • Arteriovenous Fistula
  • Arteriovenous Fistula Cannulation
  • Vascular Access
  • Vascular Access Complication

Browse trials for

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (age ≥ 18 years).

Diagnosis of end-stage kidney disease (ESKD) requiring maintenance hemodialysis (three times per week).

Reliable use of a native arteriovenous fistula (AVF) as the primary vascular access for at least the past 3 months.

Willing and able to provide written to participate in the study.

Adequate superficial venous vasculature in at least one lower extremity (e.g., dorsal foot veins, saphenous tributaries) as assessed by clinical evaluation and/or bedside ultrasound, deemed suitable for cannulation as a venous return site.

For the experimental (SNDR) group: Expressed willingness to adopt the single-needle distal return cannulation strategy.

For the control group: Currently receiving and willing to continue standard two-needle AVF cannulation.

Exclusion criteria

Exclusion Criteria:

  • Active systemic infection or localized infection at the potential cannulation sites (AVF or lower extremity veins).

Known severe coagulation disorder or thrombocytopenia ( count \< 50 × 10⁹/L) that would pose a high risk of bleeding complications from cannulation.

Severe peripheral arterial disease or venous insufficiency in the lower extremities that contraindicates venous cannulation or may compromise limb perfusion.

Unstable cardiovascular status (e.g., uncontrolled heart failure, severe arrhythmias) as determined by the treating nephrologist, which would increase the risk associated with any change in dialysis procedure.

Documented severe cognitive impairment, psychiatric illness, or any condition that would impair the ability to provide or adhere to the study protocol.

less than 12 months due to non-renal comorbid conditions (e.g., ).

Currently pregnant or breastfeeding.

Participation in another interventional clinical trial that could confound the outcomes of this study.

Anatomical or pathological condition of the AVF (e.g., extreme depth, aneurysm with overlying skin compromise, complete thrombosis) that precludes safe single-needle cannulation, as judged by the study vascular access team.

Inability to comply with the scheduled study visits and follow-up assessments.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Single-Needle Distal Return

    Procedure: Single-Needle Distal Return (SNDR) Cannulation

  • Active comparator
    Standard Two-Needle AVF Cannulation

    Procedure: Standard Two-Needle AVF Cannulation

Interventions

  • ProcedureSingle-Needle Distal Return (SNDR) Cannulation

    For each hemodialysis session, only a single needle is used to cannulate the arteriovenous fistula (AVF) to establish arterial blood inflow. The venous return is established by cannulating a superficial vein in the distal lower extremity (such as the dorsal foot vein or a tributary of the great saphenous vein), which is separate from the AVF. This approach aims to minimize repetitive trauma to the AVF segment itself.

  • ProcedureStandard Two-Needle AVF Cannulation

    For each hemodialysis session, the established standard of care is followed. This involves cannulating the arteriovenous fistula (AVF) with two separate needles: one placed proximally (or in the arterial segment) to establish blood inflow, and a second placed distally (or in the venous segment) to return dialyzed blood. This is the conventional method for maintenance hemodialysis via an AVF.

06

What researchers measure

Primary outcomes

  1. Change in dialysis adequacy (single-pool Kt/V) from baseline to study completion.

    Time frame: From enrollment to the end of the 24-month follow-up period.

  2. Annualized rate of access-related reinterventions (e.g., angioplasty, thrombectomy, surgical revision).

    Time frame: From enrollment to the end of the 24-month follow-up period.

Secondary outcomes

  1. Total access-related healthcare costs per patient-year.

    Time frame: From enrollment to the end of the 24-month follow-up period.

  2. Rate of hospitalizations primarily due to vascular access complications.

    Time frame: From enrollment to the end of the 24-month follow-up period.

  3. Incidence of cannulation-related adverse events (e.g., hematoma, infection, severe bleeding).

    Time frame: Assessed at each hemodialysis session throughout the study, up to 24 months.

  4. Proportion of hemodialysis sessions with significant machine alarms requiring staff intervention.

    Time frame: Assessed at each hemodialysis session throughout the study, up to 24 months.

  5. Patient-reported tolerance and satisfaction assessed via a standardized questionnaire.

    Time frame: At 6 months, 12 months, and at study completion (24 months).

07

Study locations

1 of 1 sites recruiting
  • Suzhou Hospital Affiliated to Anhui Medical University
    Suzhou, Anhui, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2026, 0 months later.

Of 58 non-industry interventional studies with no phase under Arteriovenous Fistula, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 43. This study's planned 0 months is below that.

Counting every sponsor, half of 84 studies reached it within 21 months; a quarter within 8 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2026
First posted
Jan 28, 2026
StartEst.
Dec 15, 2026
Primary completionEst.
Dec 20, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07372027
Lead sponsor
Suzhou Municipal Hospital of Anhui Province
Responsible party
Sponsor
First posted
Jan 28, 2026
Start date
Dec 15, 2026 (estimated)
Primary completion
Dec 20, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 28, 2026

Study contacts

Shan Wu, Doctor of Philosophy
Contact
2671437948@qq.com
86-0557-3032255

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion